Search results
Showing 31 to 45 of 51 results for hyperplasia
This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.
Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)
NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
This advice has been updated and replaced by NICE medical technologies guidance 49.
GreenLight XPS for treating benign prostatic hyperplasia (MTG74)
We have moved Medical technologies guidance 74 to become HealthTech guidance 650. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
GreenLight XPS for treating benign prostatic hyperplasia (MTG29)
This guidance has been updated and replaced by NICE healthtech guidance 650.
Prostate artery embolisation for benign prostatic hyperplasia (IPG453)
This guidance has been updated and replaced by NICE interventional procedures guidance 611.
Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)
This evidence summary has been updated and replaced by NICE guideline CG97.
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)
We have moved Medical technologies guidance 58 to become HealthTech guidance 578. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26)
This guidance has been updated and replaced by NICE healthtech guidance 578.
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)
We have moved Medical technologies guidance 49 to become HealthTech guidance 545. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved interventional procedures guidance 611 to become HealthTech guidance 469. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved interventional procedures guidance 798 to become HealthTech guidance 737. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.